Kai Xu

Statistics

Publications

Citations

H-Index

Active since

2024

Affiliations

Nanjing Medical University(Current)

China Pharmaceutical University

Fujian Medical University

Fujian Provincial Cancer Hospital

Kai Xu is an author at Nanjing Medical University specializing in willingness-to-pay thresholds, hepatocellular carcinoma pharmacotherapy, and sorafenib therapy.

ORCID

Publications per year

2024–2025

Publications

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China

Jingxuan Wei, Kai Xu, Yingtao Lin et al. · International Journal of Clinical Pharmacy · 2024 · 15 citations

Medicine, Oncology, Pharmacology +15

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis

Kai Xu, Man Yu, Qingli Sun et al. · Annals of Medicine · 2025 · 11 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

1–2 of 2